Financial Survey: NovoCure (NASDAQ:NVCR) vs. Ambu A/S (OTCMKTS:AMBBY)

NovoCure (NASDAQ:NVCR) and Ambu A/S (OTCMKTS:AMBBY) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares NovoCure and Ambu A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
Ambu A/S	8.18%	8.49%	6.75%

Risk and Volatility

NovoCure has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Ambu A/S has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

84.6% of NovoCure shares are held by institutional investors. 6.6% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares NovoCure and Ambu A/S”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$699.19 million	2.44	-$136.23 million	($1.30)	-11.29
Ambu A/S	$894.37 million	3.06	$90.19 million	$0.30	38.80

Ambu A/S has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Ambu A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for NovoCure and Ambu A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1	4	2	0	2.14
Ambu A/S	0	1	0	0	2.00

NovoCure currently has a consensus price target of $21.20, indicating a potential upside of 44.41%. Given NovoCure’s stronger consensus rating and higher probable upside, research analysts clearly believe NovoCure is more favorable than Ambu A/S.

Summary

Ambu A/S beats NovoCure on 8 of the 14 factors compared between the two stocks.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

About Ambu A/S

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, CPR breathing barriers, video laryngoscopes, and training manikins. The company was founded in 1937 and is headquartered in Ballerup, Denmark.